Further evidence for PDGFRβ as a clinically relevant predictive biomarker has been obtained from post hoc analyses of tissue collections from two randomized adjuvant radiotherapy trials in DCIS and stage I/IIA breast cancer [97, 109]. The gene discussed is PDGFRB; the disease is breast carcinoma.